| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Orchestra BioMed Holdings, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 15,000,000 shares (the “Firm Shares”) of Common Stock, ... |
| 01 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
330 patients randomized as of September 30, 2026, surpassing full trial enrollment target |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure
Accelerating high - impact technologies to patients through risk - reward sharing partnerships Corporate Overview | September 2026 Nasdaq : OBIO |
| 23 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 23, 2026, Orchestra BioMed Holdings, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 59,880,715 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock... |
| 13 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On February 12, 2026, the Board of Directors (the “Board”) of Orchestra BioMed Holdings, Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board (the “Compensation Committee”), approved the 2026 cash bonu... |
| 12 Jan 2026 |
8-K: Other Events
$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnouts |
| 13 Nov 2025 |
8-K: Regulation FD Disclosure
David Hochman, Chairman, Chief Executive Officer and Founder |
| 30 Oct 2025 |
8-K: Regulation FD Disclosure
Orchestra BioMed Corporate Overview October 2025 Nasdaq: OBIO |
| 28 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more
This STOCK PURCHASE AGREEMENT (this “Agreement”) is dated as of October 24, 2025, by and between Orchestra BioMed Holdings, Inc., a Delaware corporation (the “Issuer”), and Terumo Medical Corporation, a Delaware corporation (the “Investo... |
| 04 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
Orchestra BioMed Holdings, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) (i) an aggregate of 9,413,637 shares (the “Firm Shares”) of Common Stoc... |
| 31 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +3 more
*** Certain information in this document has been excluded pursuant to Regulation S-K, item 601(b)(10). Such excluded information is not material and is information that the company treats as private or confidential. Such omitted informa... |
| 24 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 24, 2025, Orchestra BioMed Holdings, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 38,312,512 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock... |
| 29 Apr 2025 |
8-K: Regulation FD Disclosure; Other Events
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon |
| 03 Mar 2025 |
8-K: Regulation FD Disclosure
ͮŽƌƉŽƌĂƚĞWƌĞƐĞŶƚĂƚŝŽŶY ϭϮϬϮϱ Ϯ Forward - Looking Statements This presentation has been prepared for informational purposes only from information supplied by Orchestra BioMed Holdings, Inc . , referred to herein as “we,” “our,” “Orc... |
| 25 Feb 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Policy With Respect to the Payment of Taxes Upon Vesting of Restricted Stock Units for Section 16 Officers |
| 05 Feb 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors |
| 12 Aug 2024 |
8-K: Other Events
Orchestra BioMed Holdings, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through TD Securities (USA) LLC, as sales agent and/or principal (t... |
| 30 Jul 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
John Mack brings over 30 years of diverse medical device and healthcare technology experience to the Orchestra BioMed Board of Directors |
| 20 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
On June 20, 2024, Orchestra BioMed Holdings, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 35,786,497 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock... |
| 11 Jun 2024 |
8-K: Regulation FD Disclosure
Bringing medical inn vation to life Orchestra BioMed AVIM Therapy R&D DAY June 11, 2024 |
Loading...